This site is intended for healthcare professionals
  • Home
  • /
  • News
  • /
  • 2022
  • /
  • 1
  • /
  • New Vaxzevria data further support its use as thir...
News

New Vaxzevria data further support its use as third dose booster.

Read time: 1 mins
Published:14th Jan 2022
Positive results from a preliminary analysis of an ongoing safety and immunogenicity trial (D7220C00001) showed that Vaxzevria (ChAdOx1-S [Recombinant]), when given as a third dose booster, increased the immune response to Beta, Delta, Alpha and Gamma SARS-CoV-2 variants, while a separate analysis of samples from the trial showed increased antibody response to the Omicron variant.

The results were observed among individuals previously vaccinated with either Vaxzevria or an mRNA vaccine. A separate Phase IV trial reported in a preprint with The Lancet on SSRN showed that a third dose of Vaxzevria substantially increased antibody levels following a primary vaccine series with CoronaVac (Sinovac Biotech). These data add to the growing body of evidence supporting Vaxzevria as a third dose booster irrespective of the primary vaccination schedules tested. The Company is submitting these additional data to health authorities around the world given the urgent need for third dose boosters.

See-Costa Clemens SA, et al. "Randomized immunogenicity and safety study of heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 Vaccine". Preprint 2021. Available at SSRN: https://ssrn.com/abstract=3989848 [Last accessed: January 2022]. Preprints with The Lancet available via the SSRN platform are not Lancet publications and have not been peer-reviewed.

Condition: Coronavirus/COVID-19 Infection
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.